New drug combo offers hope for Tough-to-Treat colon cancer

NCT ID NCT03829462

First seen Nov 21, 2025 · Last updated May 08, 2026 · Updated 18 times

Summary

This study tests whether combining two drugs (regorafenib and irinotecan) works better than regorafenib alone for people with metastatic colorectal cancer who have run out of standard treatment options. About 377 adults with a specific genetic marker (A/A genotype of cyclin D1) will take part. The goal is to see if the combination helps them live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CRLC Val d'Aurelle-Paul Lamarque

    Montpellier, 34298, France

  • Centre Antoine Lacassagne

    Nice, Alpes-Maritimes, 06189, France

  • Centre François Baclesse

    Caen, Basse-Normandie, 14000, France

  • Centre Léon Bérard

    Lyon, Rhône, 69008, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital Pontchaillou

    Rennes, Ile Et Vilaine, 35000, France

  • Hôpital Robert Debré

    Reims, Marne, 51100, France

  • Hôpital Saint-Jean

    Perpignan, Pyrénées-orientales, 66000, France

  • Hôpital privé Jean Mermoz

    Lyon, Rhône, 69008, France

  • Institut Godinot

    Reims, Marne, 51100, France

  • Institut Gustave Roussy

    Villejuif, Val De Marne, 94800, France

Conditions

Explore the condition pages connected to this study.